Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Hospitalization with COVID-19 pneumonia confirmed by a positive polymerase chain reaction (PCR) of any specimen \[e.g., respiratory, blood, urine, stool, and other bodily fluids\]) and evidence of pneumonia on chest X-ray or computed tomography scan~* For severe patients, SpO2 \</= 93% or PaO2/FiO2 \< 300 mmHg. If a participant is on supplemental oxygen with SpO2 \> 93%, but desaturation \</= to 93% on lower supplemental oxygen or ambient air is documented during screening, the inclusion criterion is met~* For moderate patients (those who do not qualify as severe based oxygen requirements), CRP \> 2 x upper limit of normal (ULN) is required~* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, as defined by the protocol~* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined by the protocol~Exclusion Criteria~* Known severe allergic reactions to TCZ or other monoclonal antibodies~* Active tuberculosis (TB) infection~* Suspected active bacterial, fungal, viral, or other infection (besides SARS-CoV-2)~* Participants who are on a mechanical ventilator \> 24 hours or extracorporeal membrane oxygenation (ECMO), in shock, or combination thereof with other organ failure requiring treatment in an ICU~* In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments~* Receipt of oral anti-rejection or immunomodulatory drugs (including TCZ) within the past 3 months~* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 10 x ULN detected within 24 hours at screening or at baseline (according to local laboratory reference ranges)~* Absolute neutrophil count (ANC) \< 1000/uL at screening and baseline (according to local laboratory reference ranges)~* Platelet count \< 50,000/uL at screening and baseline (according to local laboratory reference ranges)~* Pregnancy or breastfeeding, or positive pregnancy test at a predose examination~* Treatment with an investigational drug within 5 drug-elimination half-lives or 30 days (whichever is longer) of randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TCZ 8 mg/kg (Type: ACTIVE_COMPARATOR): Participants will receive intravenous (IV) tocilizumab (TCZ) at a dose of 8 mg/kg in addition to standard-of-care treatment.
- TCZ 4 mg/kg (Type: EXPERIMENTAL): Participants will receive IV tocilizumab (TCZ) at a dose of 4 mg/kg in addition to standard-of-care treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).